Avanos Medical (AVNS)
(Delayed Data from NYSE)
$22.80 USD
+0.15 (0.66%)
Updated Oct 15, 2024 04:00 PM ET
After-Market: $22.81 +0.01 (0.04%) 7:58 PM ET
2-Buy of 5 2
B Value D Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$22.80 USD
+0.15 (0.66%)
Updated Oct 15, 2024 04:00 PM ET
After-Market: $22.81 +0.01 (0.04%) 7:58 PM ET
2-Buy of 5 2
B Value D Growth C Momentum C VGM
Zacks News
National Vision (EYE) Rides on Comps Growth Amid Macro Issues
by Zacks Equity Research
National Vision (EYE) continues to roll out its remote care capabilities, which provide doctors with additional levels of flexibility and expand exam capacity in many areas.
3 Reasons to Add Avanos (AVNS) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Avanos (AVNS) owing to its strong product line and focus on R&D.
Illumina (ILMN) to Expand Genomics Capacity With New Pact
by Zacks Equity Research
Illumina's (ILMN) recent collaboration is built on the shared goal of the organizations to expand sequencing capabilities and capacity for all people in Africa.
Here's Why Investors Should Invest in Zimmer Biomet (ZBH) Now
by Zacks Equity Research
Investors are optimistic about Zimmer Biomet (ZBH) on strong elective procedure recovery and commercial execution.
Illumina's (ILMN) NovaSeq X Exceeds 200 Order Milestone
by Zacks Equity Research
Illumina's (ILMN) NovaSeq X records the strongest pre-launch demand ever witnessed for any instrument.
3 Reasons to Retain Integer Holdings (ITGR) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Integer Holdings (ITGR) owing to its improving non-medical sales and a solid foothold in the broader MedTech space.
CVS Health's (CVS) New Initiatives Aid, Margin Woes Linger
by Zacks Equity Research
CVS Health (CVS) launches functionality that gives patients more choices and convenience in filling prescriptions.
Cardiovascular Systems (CSII) Finishes ECLIPSE Trial Enrollment
by Zacks Equity Research
Cardiovascular Systems' (CSII) ECLIPSE clinical trial data is likely to help physicians form an optimal treatment plan for patients with severely calcified coronary arteries.
Community Health (CYH) Divests Hospital for $92 Million
by Zacks Equity Research
Community Health (CYH) divests a healthcare facility in West Virginia, thereby reinforcing the sincere focus that it puts to shed non-core assets and use funds to grow well-performing business areas.
LabCorp (LH) Expands Colon Cancer Test Access With New Pact
by Zacks Equity Research
LabCorp's (LH) at-home collection kit will offer patients an additional and easier option to get screened for colon cancer.
Here's Why You Should Invest in Haemonetics (HAE) Right Now
by Zacks Equity Research
Investors are upbeat about Haemonetics (HAE) owing to impressive Plasma and Hospital business performance, with continued strength in the Hemostasis Management product line.
3 Reasons to Retain AMN Healthcare (AMN) Stock in Your Portfolio
by Zacks Equity Research
Investors are optimistic about AMN Healthcare's (AMN) broad array of services.
Masimo's (MASI) New FDA Clearance to Boost Patient Monitoring
by Zacks Equity Research
Masimo's (MASI) receipt of the FDA's De Novo grant is expected to combat opioid overdoses by boosting patient monitoring.
3 Reasons to Retain PacBio (PACB) Stock in Your Portfolio
by Zacks Equity Research
PacBio's (PACB) product development activities raise optimism about the stock.
Medtronic (MDT) Launches New Venture to Treat Kidney Failure
by Zacks Equity Research
Medtronic's (MDT) new venture is dedicated to reshaping kidney health and driving patient-centered technology solutions.
Tandem Diabetes (TNDM) Gains on Pump Sales, Margin Woe Stays
by Zacks Equity Research
Tandem Diabetes (TNDM) is now increasing its renewal numbers both in volume and rates.
Why You Should Add Hologic (HOLX) to Your Portfolio Now
by Zacks Equity Research
Hologic (HOLX) is currently well-positioned to achieve its full-year guidance of low double-digit organic growth ex-COVID in all three franchises, well above the 5-7% long-term growth rate.
Abbott's (ABT) Epic Max Tissue Valve Receives FDA Approval
by Zacks Equity Research
Abbott's (ABT) Epic Max design optimizes patient blood flow and has a low profile that makes future cardiac interventions simpler.
3 Reasons to Retain DaVita (DVA) Stock in Your Portfolio
by Zacks Equity Research
Investors remain optimistic about DaVita (DVA) due to the strength in its DaVita Kidney Care.
Neogen (NEOG) Q3 Earnings Beat Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Neogen (NEOG) delivers core growth in both the Food Safety and Animal Safety segments amid macroeconomic headwinds in the third quarter.
Catalent (CTLT) New Launch to Aid TPD Programs, Clinical Trials
by Zacks Equity Research
Catalent's (CTLT) latest launch will likely aid in advancing the rational selection of orally developable TPD candidates and their progress into clinical trials.
UnitedHealth (UNH) Arm to Reduce Prior Authorization Time
by Zacks Equity Research
UnitedHealth's (UNH) UnitedHealthcare business to lower the use of prior authorization process or preauthorization by almost 20%.
Tenet Healthcare (THC) Jumps 14.9% YTD: More Growth Ahead?
by Zacks Equity Research
Tenet Healthcare's (THC) focus on boosting USPI's network is positioning the company for expedited growth.
QIAGEN (QGEN) QIAxcel Connect Gets Red Dot Design Award
by Zacks Equity Research
QIAGEN (QGEN) QIAxcel Connect automates the analysis of the size and quality of isolated DNA and RNA.
Teleflex (TFX) Urolift Market Expansion Strong, Cost Woe Stays
by Zacks Equity Research
Teleflex (TFX) plans to spend 2023 training surgeons, building its presence in key cities and continuing to engage with the Chinese Urological Society to build acceptance.